|
|
|
11-50 employees
View all
|
|
biotechnology
|
|
San Diego, CA, US
|
|
Stemedica Cell Technologies, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of progenitor cell and protein therapeutics for underserved medical conditions. Stemedica has developed a proprietary manufacturing technology platform that produces allogeneic progenitor cell products with intellectual property protection under a low-oxygen, low-tension environment in a cGMP-compliant manufacturing facility. The company's lead drug candidate, ischemia-tolerant mesenchymal stem cells, or itMSCs, is an allogeneic progenitor cell therapy currently in clinical development for the treatment of ischemic stroke and Alzheimer’s disease. The company’s second drug candidate, ischemia-tolerant neural progenitor cells, or itNSCs, is an allogeneic cell therapy currently in development for spinal cord injury. In addition, Stemedica is developing progenitor multi-cell therapy (itMSCs and itNSCs) for ischemic stroke and progenitor cell and protein combination therapy for Alzheimer’s disease. More information on Stemedica may be found at www.stemedica.com.
|
Stemedica Cell Technologies, Inc Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
80%
|
The widely used Stemedica Cell Technologies, Inc email format is {f}{last} (e.g. [email protected]) with 80% adoption across the company.
To contact Stemedica Cell Technologies, Inc customer service number in your country click here to find.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.